• ST Pharm has completed the patent registration in Japan for the key technology of its mRNA platform, 5' capping.
• The present invention relates to a novel oligonucleotide primer used for the synthesis of 5'-capped RNA. It can be effectively utilized in the fields of nucleic acid therapeutics or vaccines.
• SMARTCAP® patents have been registered in South Korea and Japan, and are now pending in the United States, Europe, China, India, Canada, Israel, Thailand, and Vietnam.

[Registration information]
Invention Title: OLIGONUCLEOTIDE FOR 5'-CAPPED RNA SYNTHESIS
Patent Number: 7644229